PETER H. VLASSES, Pharm.D.; MARIO L. ROCCI Jr., Ph.D.; KAREN A. PORRINI, Pharm.D.; ARNOLD J. GREENSPON, M.D.; ROGER K. FERGUSON, M.D.
Procainamide is effective in the prevention or treatment of various cardiac arrhythmias. Maintaining serum procainamide concentrations in the therapeutic range has been identified as an important factor in preventing the recurrence of cardiac arrest independent of suppression of ventricular ectopic activity (1). Because of its relatively short serum half-life, procainamide usually must be administered every 3 to 4 hours, at great inconvenience to the patient, in order to maintain effective serum concentrations and prevent excessive fluctuations above or below the therapeutic range (2). A recently marketed, sustained-release dosage form of procainamide, Procan-SR (Parke-Davis, Morris Plains, New Jersey), has been found
VLASSES PH, ROCCI ML, PORRINI KA, GREENSPON AJ, FERGUSON RK. Immediate-Release and Sustained-Release Procainamide: Bioavailability at Steady State in Cardiac Patients. Ann Intern Med. 1983;98:613–614. doi: 10.7326/0003-4819-98-5-613
Download citation file:
Published: Ann Intern Med. 1983;98(5_Part_1):613-614.
Cardiology, Rhythm Disorders and Devices.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use